1. Role: Associate Dean. Scope: College. Description: Lead research enterprise of the College of Pharmacy. Represent the College at the HSC level. Mentor researchers. Date: 2020.
Vibhudutta Awasthi, Ph.D.
Professor and Associate Dean for Research
Pharmaceutical Sciences
Phone (405) 271-6593 x47331
Fax (405) -271-7505
Office CPB 309
Summary
My research interests are in the development of radiopharmaceuticals, small animal imaging and use of radiological imaging techniques to answer physiological questions. My current research focuses on the development of liposome encapsulated hemoglobin as an artificial oxygen carrier and he is studying cerebral oxygen metabolism using positron emission tomography. I am a board certified nuclear pharmacist with expertise in areas related to drug delivery, formulation development, nuclear pharmacy and small animal nuclear imaging.
Publications & Presentations
- 61. Awasthi V, Nag O. Surface engineering of liposomes for stealth behavior. Pharmaceutics. 2013; 5 : 542-569
62. Pathuri G, Hedrick A F, Awasthi V, Ihnat M, Gali H. Evaluation of 99mTc-probestin for imaging APN expressing tumors by SPECT. Bioorg Med Chem Lett. 2013; 23 : 5049-52
63. Yadav V, Sahoo K, Awasthi V. Pharmacologic suppression of inflammation by a dipheyldifluoroketone, EF24, in a rat model of fixed-volume hemorrhage improves survival. J Pharmacol Exp Ther . 2013; 347 : 346-356
64. Aravindan S, Natarajan M, Awasthi V, Herman T S, Aravindan N. Novel synthetic monoketone transmute radiation-triggered NFκB-dependent TNFα cross-signaling feedback maintained NFκB and favors neuroblastoma regression. PLoS One. 2013; 8 : e72464
65. Lagisetty P, Agashe H, Awasthi V. 2-[3,5-bis-(2-fluorobenzylidene)-4-piperidon-1-yl]-N-(4-fluorobenzyl)-acetamide and its evaluation as an anticancer agent. Journal of Chemistry. 2013
Grants
- 1. Developing PPARγ acetylation inhibitor for the treatment of aging-related conditions. NIH. Start Date: 2021. End Date: 2026.
2. Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment. NIH. Start Date: 2021. End Date: 2026.
3. SBIR Phase I: Early-Stage Development of GPPD for Fatty Liver. NIH.
4. Surfactant protein-A regions as TLR4-immunomodulators. NIH. Start Date: 2017. End Date: 2023.
5. STTR Phase I: Cardiotropic Atorvastatin Liposomes for Myocardial Reperfusion Injury. NSF. Start Date: 2023. End Date: 2021.
Awards and Honors
- 1. USPTO. Patent application issued. Date: 2015.
2. Journal of Pharmaceutical Sciences. Article selected as a featured research paper. Date: 2015.
3. Robert Glenn Rapp Foundation. Presidential Professor . Date: 2013.
4. Sandra K and David L Gilliland Chair in Nuclear Pharmacy . Date: 2012.
Education
- 1. Degree: Ph D. Sanjay Gandhi Postgraduate Institute of Medical Sciences . Date: 1994.
2. Degree: M. Pharm.. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1990.
3. Degree: B. Pharm. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1988.
Administrative Assignments
2. Role: Director. Scope: University. Description: Direction and conduct of nuclear imaging services for biomedical investigators; Production of PET radiotracers for preclinical imaging and preparation for regulatory compliance for clinical applications; Consultations with researchers about imaging and tracer applications. Date: 2007.
External Connections and Partnerships
no results